UCB SA (UCB-BT)

QUOTE AND NEWS
Financial Times  Nov 7  Comment 
Generics sale highlights growth of ‘precision M&A’
TheStreet.com  Nov 7  Comment 
Belgian drugmaker UCB SA announced an agreement Friday, Nov. 7, to sell Princeton, N.J.-based generics maker Kremers Urban Pharmaceuticals Inc. to buyout shops Advent International Corp. and Avista Capital Partners for $1.53 billion. The deal...
FiercePharma  Nov 7  Comment 
Amid the pharma's slimdown craze, Belgium's UCB is getting in on the action by selling its U.S. generic drug unit for $1.53 billion.
Reuters  Oct 22  Comment 
A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc,...
Benzinga  Oct 22  Comment 
IMS Health (NYSE: IMS) today announced that it has entered into an innovative collaboration with UCB to help deliver greater business insights and improved operations, leveraging IMS Health's Nexxus™ Commercial Application Suite and the IMS...
StreetInsider.com  Sep 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amgen+%28AMGN%29%2C+UCB+Present+Data+from+Romosozumab+Phase+2+in+Postmenopausal+Women+with+Low+BMD/9832979.html for the full story.
FiercePharma  Sep 12  Comment 
The threat of action from lawmakers may have put a damper on pharma's tax inversion frenzy, but it has not stopped the wave of deals that are taking American drugmakers overseas. Next up could be Illinois' Akorn, which is reportedly looking into a...
Reuters  Sep 11  Comment 
U.S. specialty drugmaker Akorn Inc is exploring a bid for Belgian drugmaker UCB SA's U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas in a...
SeekingAlpha  Aug 8  Comment 
This week’s patent expirations are related to UCB’s (OTCPK:UCBJF) Vimpat, a seizure medication, and Genentech’s [now owned by Roche (OTCQX:RHHBY)] Nutropin Depot. Vimpat Vimpat launched in 2009 as an...





You may also be interested in articles related to UCB SA (UCB-BT):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki